Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
A study of the safety and feasibility of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in patients with newly diagnosed high risk neuroblastoma.
A confirmed diagnosis of neuroblastoma. Must be 21 years of age or younger when diagnosed. No prior systemic therapy with some exceptions. Tumor samples will be obtained only in a non-significant risk manner and not solely for the purpose of the study.
Exclusion Criteria:
Receiving another study drug while on this study. Female patients who are lactating are not eligible unless they agree not toe breast feed.